Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Characterization of anti-natalizumab antibodies in multiple sclerosis patients.
Another promising oral agent for multiple sclerosis.
Natalizumab: Bench to Bedside and Beyond.
Humoral-Targeted Immunotherapies in Multiple Sclerosis.
What is the relevance of quality of life assessment for patients with attention impairment?
Autoantigens and autoantibodies in multiple sclerosis.
Faith as a resource in patients with multiple sclerosis is associated with a positive interpretation of illness and experience of gratitude/awe.
A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis.
Tropical myelopathies.
RORγt Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis.
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study.
Pathologic laughing as a presenting feature in a patient with neuromyelitis optica.
n-3 PUFAs Reduce T-Helper 17 Differentiation by Decreasing Responsiveness to Interleukin-6 in Isolated Splenic Mouse CD4+ T Cells.
Epstein-Barr virus in multiple sclerosis.
Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases.
Spiritual wellbeing and perceived uncertainty in patients with multiple sclerosis in south-east Iran.
Class II HLA interactions modulate genetic risk for multiple sclerosis.
Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis.
Nutraceuticals against Neurodegeneration: A Mechanistic Insight.
Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers.
Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system.
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.
Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis.
Pages
« first
‹ previous
…
396
397
398
399
400
401
402
403
404
…
next ›
last »